Overview

A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment

Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
An oral dose of BMS-986177 administered in End-stage Renal Dysfunction (ESRD) participants before and after a hemodialysis session to evaluate safety, tolerability, and pharmacokinetics in this patient population.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb